Development of a systemic anti-cancer therapy algorithm

Introduction

The following review questions were identified and included in the scope for the update of Lung cancer: diagnosis and management guideline (CG 121):

What is the clinical and cost effectiveness of the following systemic anti-cancer therapy regimens for treating NSCLC?

- platinum combinations compared with non-platinum combinations in people with advanced NSCLC (stage III or IV)
- non-platinum monotherapy compared with non-platinum combinations in people with advanced NSCLC (stage III or IV) who cannot tolerate platinum combinations

New evidence was identified during the 4-year surveillance process that may change current recommendations. This included systematic review evidence on gemcitabine plus paclitaxel and docetaxel-based doublet therapy and new RCT evidence on third-generation drugs plus platinum drugs.

The guideline committee discussed the review questions and the need for clinical guidance in this area and agreed that instead of updating the chemotherapy for NSCLC recommendations (recommendations 1.4.40 – 1.4.43) the guideline update should develop an algorithm outlining the treatment pathway for systemic anti-cancer therapy treatments. This algorithm would provide a clear overview and contextualisation of systemic anti-cancer therapy treatments.

Methods and Process

The algorithms were drafted based on effectiveness and cost effectiveness recommendations from all relevant Technology Appraisals (TAs) for non-small cell lung cancer alongside expert clinical knowledge provided by the guideline committee. Additionally systematic anti-cancer therapy recommendations to support the algorithms were agreed based on recommendations from the relevant TAs.

Targeted Expert Engagement

A pre-consultation engagement exercise was agreed to support the development of the algorithms by providing selected expert groups the opportunity to review the draft algorithms ahead of the formal public stakeholder consultation.

The targeted engagement exercise is summarised below:
• The guideline committee identified the British Thoracic Oncology Group and the British Thoracic Society as professional bodies whose membership has expert knowledge of systemic anti-cancer therapy.

• Ten survey questions were drafted including seven closed and three open questions.

• The survey was administered online with a web link sent to participating organisations requesting that the survey be shared with their membership and completed online. The survey was open from 11th May to 3rd June 2018, with reminder emails, to promote a greater response.

• Additionally the Lung Cancer Clinical Expert Group (CEG) were contacted. Rather than completing the survey this stakeholder provided a series of individual comments which contributed towards the development of the algorithm.

• A second round of engagement with the Lung Cancer CEG was conducted following revision of the draft algorithm.

Results

British Thoracic Oncology Group and the British Thoracic Society (online survey)

A total of 3 responses were received from the online survey.
Lung cancer - targeted consultation - 3 survey results received

Q2  Do you think the algorithm is organised in a helpful and understandable way?

<table>
<thead>
<tr>
<th>RESPONSES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes 2</td>
</tr>
</tbody>
</table>

Q3  Do you think the algorithm is organised in a helpful and understandable way? Please explain your response

<table>
<thead>
<tr>
<th>RESPONSES</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
</tr>
</tbody>
</table>

It’s quite confusing in the top algorithm with the arrows switching sides. Would it be better for 1 algorithm with targetable mutations and one without? Each individual side is easy to follow.

There are a few omissions and inaccuracies which have been corrected.

Q4  The current Lung Cancer diagnosis and management update (CG121) recommends the below: Chemotherapy for advanced NSCLC should be a combination of a single third generation drug (docetaxel, gemcitabine, paclitaxel or vinorelbine) plus a platinum drug. Either carboplatin or cisplatin may be administered, taking account of their toxicities, efficacy and convenience. [2005 CGC 121 recommendation]

The update committee would like to remove docetaxel from this recommendation as they are of the view that docetaxel should not be used with a platinum drug.

Do you agree?

<table>
<thead>
<tr>
<th>RESPONSES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes 1</td>
</tr>
</tbody>
</table>

Q4  If you disagree, please explain why?

Docetaxel and carboplatin is a valid combination licensed and appraised. Not used very much but should be included as an option.

Q5  Please review the statements below and rate them on your level of agreement, 1 being strongly disagree, 5 being strongly agree.

Q5a  The algorithm and recommendations reflect best clinical practice

<table>
<thead>
<tr>
<th>RESPONSES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strongly disagree</td>
</tr>
<tr>
<td>1</td>
</tr>
</tbody>
</table>

Q5b  The algorithm and recommendations reflect the wording and intentions of NICE’s guidance in this area to date

<table>
<thead>
<tr>
<th>RESPONSES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strongly disagree</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>Q6</td>
</tr>
<tr>
<td>----</td>
</tr>
<tr>
<td><strong>RESPONSES</strong></td>
</tr>
<tr>
<td>Consider carboplatin as well as cisplatin in recommending platinum based chemotherapy</td>
</tr>
<tr>
<td>Generally fit for purpose and reflect NICE guidance but some inaccuracies which have been corrected on behalf of BTOG and returned to NICE</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Q7</th>
<th><strong>Are you aware of any regional variation in the implementation of systematic anti-cancer therapy guideline recommendations?</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RESPONSES</strong></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>2</td>
</tr>
<tr>
<td>No</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Q7a</th>
<th><strong>If yes, please explain</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RESPONSES</strong></td>
<td>Access to better diagnostics and pathology. Knowledge of access of drugs through cdf as very frequent changes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Q8</th>
<th><strong>Finally, how can the algorithm be improved (if at all)? Please use the box to suggest any changes you think should be made?</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RESPONSES</strong></td>
<td>Algorithm amended on behalf of BTOG Main division should be squamous vs nonsquamous PDL1 &gt;50% and &gt;1-49% and unknown Nivolumab TA484 omitted please see amendments</td>
</tr>
</tbody>
</table>

---

**Lung Cancer Clinical Expert Group (CEG)**

Comments from the first round of engagement with the Lung Cancer (CEG) are summarised below:

- There is a clear need for the algorithms to reflect current clinical practice alongside the recommendations from relevant technology appraisal (TA) guidance.

- The algorithms will require updating as new evidence emerges either through research or the publication of further TA guidance.

- Identification of a number of factual errors in the initial draft algorithms particularly in relation to genetic markers for disease, the possible variations in 1st, 2nd and 3rd line treatment based on clinical practice and the overall presentation of the algorithms e.g. by histology or squamous/ non-squamous sub-type.

Comments from the second round of engagement with the Lung Cancer (CEG) are summarised below:
The systematic anti-cancer therapy recommendations were considered repetitive for the reader and would be better paraphrased.

The need to keep the algorithm updated was again emphasised.

The recommendations need to include the caveats imposed on the Cancer Drug Fund.

The need to take into account the further restrictions in practice imposed by accessing therapies through the Blueteq system.

The algorithm does not reflect current practice as this is driven by the NHS England’s permissions stated by each CDF drug indication which is usually a more limited remit of the NICE approved indication.

Committee Discussion

The committee discussed the outcome of the online survey and the feedback received from the CEG. It was agreed that the results from the online survey were limited and mixed. Therefore they provided no clear direction for further development of the algorithms.

The Lung Cancer CEG comments were discussed by the guideline committee and further revisions made. The committee had initially proposed removing recommendation 1.4.41 which recommends docetaxel combined with a platinum drug for advanced NSCLC as they considered this combination to be toxic and poorly tolerated by patients. However comments from the lung cancer CEG indicated that experts were content to keep docetaxel combined with a platinum drug for advanced NSCLC as an option for systemic therapy. This treatment option has therefore remained.

The committee discussed the difficulties in developing a set of algorithms which are able to reflect NICE’s TAs in the context of clinical practice and recommended that the algorithm be adapted from a published algorithm developed by Rhiannon Walters-Davies and Anthony Pope (Clinical Pharmacist, June 2018, Volume 10 (6)). Copyright permission was obtained by NICE to use this published algorithm although some modifications were made in line with comments received and using the wider experience and expertise of the committee.

A set of written recommendations were also discussed and agreed by the committee to support the algorithms.
Appendix 1 - Systemic anti-cancer therapy algorithms – non-squamous and squamous
Systemic anti-cancer therapy: management options for people with non-squamous (adenocarcinoma, large cell undifferentiated) carcinoma and non-small cell carcinoma (non-otherwise specified)

No gene mutation or fusion protein and PD-L1 <50%

- EGFR positive
  - Atezolizumab (TA310) or Erlotinib (TA258) or Gefitinib (TA192)

  - T790M positive?
    - Yes
      - Osimertinib (TA416)
    - No
      - Crizotinib (TA422)

- ALK positive
  - Ceritinib (TA500)
  - Nintedanib (TA347)

- ROS-1 positive
  - Crizotinib (TA529)

- PD-L1 ≥50%
  - Pembrolizumab (TA531)

Platinum doublet chemotherapy

Pemetrexed maintenance (TA402 or TA190)

- Atezolizumab (no PD-L1 expression needed) (TA520)
- Nivolumab (if PD-L1 ≥1%) (TA484)
- Pembrolizumab (if PD-L1 >1%) (TA428)

- Docetaxel +/- Nintedanib (TA347)

Cancer Drugs Fund

This combination/some of these combinations of drugs do not have a UK marketing authorisation for this indication

National Institute for Health and Care Excellence


© NICE 2018. All rights reserved. Subject to notice of rights
Systemic anti-cancer therapy: management options for people with squamous non-small cell carcinoma

PD-L1 <50%
- Gemcitabine + Carboplatin* or Cisplatin
- Atezolizumab (no PD-L1 expression needed) (TA520)
  or Nivolumab (no PD-L1 expression needed) (TA483)
  or Pembrolizumab (if PD-L1 >1%) (TA428)
  → Disease progression

PD-L1 ≥50%
- Pembrolizumab (TA531)
- Gemcitabine + Carboplatin* or Cisplatin
- Vinorelbine + Carboplatin or Cisplatin
- Docetaxel
  → Disease progression
  → Cancer Drugs Fund
  * The gemcitabine and carboplatin combination does not have a UK marketing authorisation for this indication


© NICE 2024. All rights reserved. Subject to notice of rights.
Appendix 2 – Systemic anti-cancer therapy recommendations

Non-squamous NSCLC

EGFR-TK mutation

1. For guidance on treatment for non-squamous non-small cell lung cancer in people with the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation:
   o for initial treatment, see the NICE technology appraisal guidance on afatinib, erlotinib and gefitinib.
   o on progression for people with the EGFR T790M mutation, see the NICE technology appraisal guidance on osimertinib.
   o on progression, offer platinum doublet chemotherapy or see the NICE technology appraisal guidance on pemetrexed.
   o if patients do not immediately progress after chemotherapy, see the NICE technology appraisal guidance on pemetrexed maintenance after pemetrexed and pemetrexed maintenance after other platinum doublet chemotherapy.
   o on progression after first-line chemotherapy, offer docetaxel monotherapy or see the NICE technology appraisal guidance on atezolizumab, nivolumab and pembrolizumab and docetaxel with nintedanib.

ALK gene rearrangement

2. For guidance on treatment for non-squamous non-small cell lung cancer in people with the anaplastic lymphoma kinase-positive gene rearrangement:
   o for first-line systemic treatment, see the NICE technology appraisal guidance on crizotinib, ceritinib and alectinib.
   o on progression after first-line crizotinib, ceritinib or alectinib, see the NICE technology appraisal guidance on crizotinib and ceritinib for second line treatment.
   o on progression, offer platinum doublet chemotherapy or see the NICE technology appraisal guidance on pemetrexed.
   o if patients do not immediately progress after chemotherapy, see the NICE technology appraisal guidance on pemetrexed maintenance after pemetrexed and pemetrexed maintenance after other platinum doublet chemotherapy.
   o on progression after first-line chemotherapy, offer docetaxel monotherapy or see the NICE technology appraisal guidance on atezolizumab, nivolumab and pembrolizumab and docetaxel with nintedanib.

PDL1>=50%

3. For guidance on treatment for non-squamous non-small cell lung cancer in people whose tumours express PD-L1 at or above 50%:
   o for initial treatment, see the NICE technology appraisal guidance on pembrolizumab.
   o on progression after Pembrolizumab, offer platinum doublet chemotherapy or see the NICE technology appraisal guidance on pemetrexed.
Development of systemic anti-cancer therapy algorithm

1. If patients do not immediately progress after chemotherapy, see the NICE technology appraisal guidance on [pemetrexed maintenance after pemetrexed](#) and [pemetrexed maintenance after other platinum doublet chemotherapy](#).
2. On progression after first-line chemotherapy, offer docetaxel monotherapy or see the NICE technology appraisal guidance on [docetaxel with nintedanib](#).

**ROS-1**

4. For guidance on treatment for ROS1-positive non-squamous non-small cell lung cancer:
   - For initial treatment, the NICE technology appraisal guidance on [crizotinib](#).
   - On progression, offer platinum doublet chemotherapy or see the NICE technology appraisal guidance on [pemetrexed](#).
   - If patients do not immediately progress after chemotherapy, see the NICE technology appraisal guidance on [pemetrexed maintenance after pemetrexed](#) and [pemetrexed maintenance after other platinum doublet chemotherapy](#).
   - On progression after first line chemotherapy, offer docetaxel monotherapy or see the NICE technology appraisal guidance on [atezolizumab, nivolumab, pembrolizumab](#) and [docetaxel with nintedanib](#).

**No gene mutation, fusion protein and PD-L1<50%**

5. For guidance on treatment for non-squamous non-small cell lung cancer in people who do not have a gene mutation, fusion protein or biomarker or in whom chemotherapy is otherwise indicated:
   - Offer platinum doublet chemotherapy or see the NICE technology appraisal guidance on [pemetrexed](#).
   - If patients do not immediately progress after chemotherapy, see the NICE technology appraisal guidance on [pemetrexed maintenance after pemetrexed](#) and [pemetrexed maintenance after other platinum doublet chemotherapy](#).
   - On progression after first line chemotherapy, offer docetaxel monotherapy or see the NICE technology appraisal guidance on [atezolizumab, nivolumab, pembrolizumab](#) and [docetaxel with nintedanib](#).

**Squamous NSCLC**

PDL1>=50%

6. For guidance on treatment for squamous non-small cell lung cancer in people whose tumours express PD-L1 at or above 50%:
   - For initial treatment, see the NICE technology appraisal guidance on [pembrolizumab](#).
   - On progression, offer gemcitabine or vinorelbine and cisplatin or carboplatin.
   - On progression after first line chemotherapy, offer docetaxel monotherapy.

PDL1<50%

7. For guidance on treatment for squamous non-small cell lung cancer in people whose tumours express PD-L1 below 50% and are ROS-1 negative:
   - For initial treatment, offer gemcitabine or vinorelbine and cisplatin or carboplatin.
on progression after first line chemotherapy, see the NICE technology appraisal guidance on atezolizumab, nivolumab and pembrolizumab or offer docetaxel monotherapy.